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Abstract
Background: To determine whether dose/volume specific endpoints (DVSE) or Area under the rectal DVH curve
(rAUC) better predict acute gastrointestinal (GI) toxicity in prostate cancer patients treated with IMRT in the era of
daily image guidance (IG-IMRT).
Methods: A set of DVSE was recorded from V25 to V75 (increments of 5Gy) (both in % and in cc) for 180 men. The
rAUC was calculated for doses ranging between 25Gy and 50Gy (rAUC25–50). Univariate and multivariate logistic
regressions were performed to determine the relationship between DVSE or rAUC25–50 and the appearance of any
acute GI toxicity.
Results: The rates of acute grade 1 (G1), G2 and G3 GI toxicities were 53.3 %, 10.6 % and 1.1 %, respectively. No G4
+ toxicity was observed.
Rectal V25 to V75 expressed in % were not predictive of G ≥ 1 GI toxicity (p ≥ 0.12) whereas rectal V25 to V50
expressed in cc did correlate with GI toxicity G ≥ 1 (p ≤ 0.04). rAUC25–50 expressed in cc. Gy correlated significantly
with the occurrence of any acute GI toxicity G ≥ 1 (p = 0.027).
Conclusions: The absolute volume of the rectum between 25Gy and 50Gy and rAUC25–50 could significantly
predict any acute rectal toxicity in prostate cancer patients treated with daily IG-IMRT.
Keywords: Prostate cancer, Acute rectal toxicity predictive factor, Radiotherapy
Background
Intensity Modulated Radiation Therapy (IMRT) with daily
image guidance of soft tissues in patients with localized
prostate cancer (PCa) has been shown to improve bio-
chemical control and to reduce rectal toxicities compared
with 3-dimensional conformal radiation therapy (3D-
CRT) [1–3]. The risk of normal tissue complications is
typically evaluated from the amount of tissue exposed to a
given dose (namely, dose-volume specific endpoint
(DVSE)). For 3D-CRT, DVSE have been demonstrated to
be reliable and reproducible for predicting acute and late
toxicity according to Radiation Therapy Oncology Group
(RTOG) scoring criteria [4]. Several dose-constraint
guidelines, based on post-hoc analyses of rectal toxicity
and its correlation with each DVSE, have been established
to determine what relative volume of rectum (in %) can
safely receive high doses [5–8].
As for image-guided IMRT (IG-IMRT), there are no
robust, reproducible data in the literature to indicate
which DVSE are useful for a more accurate prediction of
acute toxicity. Guidelines used by radiation clinicians
were based on late toxicities and came mostly from 3D
conformal radiotherapy [4]. Regarding the lower rates of
rectal toxicity observed with IG-IMRT compared with
3D-CRT [9], standard DVSE developed from 3D-CRT
results could be irrelevant. Hence, new tools are needed
* Correspondence: cmirjolet@cgfl.fr
1Department of Radiation Oncology, Centre Georges Francois Leclerc, 1, rue
du Pr Marion, 21049 Dijon, France
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Mirjolet et al. Radiation Oncology  (2016) 11:145 
DOI 10.1186/s13014-016-0721-8
for IG-IMRT to improve predictions for any grade of
acute toxicity. The purpose of this study was to determine
a new type of dose/volume parameter to predict any acute
GI toxicity with daily IG-IMRT. This new parameter was
determined by studying a set of several DVSE expressed
in % and in cc. As the shape of the entire rectal DVH
curve from low to high doses cannot be reflected by one
single DVSE or even several DVSE, we also investigated
the area under the rectum DVH curve (rAUC) as a chal-
lenger for predicting acute GI toxicity.
Methods
Selection of patients
We selected 180 men with at least eight visits for toxicity
evaluations and with available DVH data. All of the men
had localized PCa treated with daily IG-IMRT with cura-
tive intent.
Characteristics of patients are summarized in Table 1.
IMRT
All patients first underwent a planning CT scan with
2.5 mm slice thickness in the supine position with knee
and ankle supports. A rectal enema was given before the
CT for each patient. They were asked to maintain the
same degree of bladder filling during the simulation and
treatment sessions. Critical normal-tissue structures
were outlined by a radiation oncologist on each axial CT
image. The rectum was defined as a cylindrical structure
around the outer rectal wall and contoured from the is-
chial tuberosities to the rectosigmoid junction, identified
in accordance with international guidelines by the level
at which the GI tract narrows and diverges anteriorly
from the rectum [4, 10].
Intensity was modulated by dynamic multileaf collima-
tion using the sliding window technique, as previously
described by our group in this journal [10, 11]. Patients
who underwent whole pelvic radiotherapy were excluded
from this study. The median dose prescribed to the
prostate PTV was 78Gy [74–80] at 2Gy per fraction and
five fractions per week.
IGRT
Daily on-line repositioning based on soft-tissues was
performed for all the patients using either kV Cone
Beam Computed Tomography or a 3D ultrasound sys-
tem as described in detail elsewhere [11, 12].
Dose/volume modeling for rectal toxicity
A set of standard DVSEs was tested: the volume of the rec-
tum receiving from 25Gy to 75Gy (V25 to V75), expressed
in percentages (%) and in cubic centimeters (cc).
Calculation of the area under the rectum DVH curve (rAUC)
In the second step, we calculated the area under the
DVH curve between 25 and 50Gy for the rectum
(rAUC25–50).
The respective rAUC, expressed in cc.Gy, were calcu-
lated every 5Gy in the following manner (Fig. 1):
rAUCdoseX‐Xþ5Gy¼5  VXþ5Gy þ 2:5  VXGy‐VXþ5Gy
 
For example (Fig. 1): rAUC25 ‐ 30 = 5 * V30 + 2.5 *
(V25 ‐ V30)
Thus, rAUC25 ‐ 50 = rAUC25 ‐ 30 + rAUC30 ‐ 35 + rAUC35 ‐ 40
+ rAUC40 ‐ 45 + rAUC45 ‐ 50
Follow-up and toxicity evaluation
Each patient was seen in our institution every week dur-
ing the radiation therapy and at 3 months and 6 months
Table 1 Characteristics of patients and treatments
All patients
N = 180
Age (median [range]) years 70.5 [49.6–84.9]
T stage-n (%)
T1c 57 (31.7 %)
T2a 31 (17.2 %)
T2b 37 (20.6 %)
T2c 19 (10.6 %)
T3a 30 (16.7 %)
T3b 6 (3.3 %)
PSA (ng/ml) (median [range]) 10 [0.8–99]
Gleason score-n (%)
≤ 6 103 (57.2 %)
7 64 (35.6 %)
≥ 8 13 (7.2 %)
Risk groups-n (%)
Low risk 48 (26.7 %)
Intermediate risk 68 (37.8 %)
High risk 64 (35.6 %)
Hormone therapy-n (%)
Neoadjuvant 50 (27.8 %)
Concomitant 69 (38.3 %)
Adjuvant 70 (38.9 %)
Radiotherapy: prostate dose (2Gy/fxa) 78 [70–80]
Median [range]
TURPb-n (%)
Yes 35 (19.7 %)
No 143 (80.3 %)
Missing 2 (1.1 %)
a fraction; b transurethral resection of the prostate
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thereafter. Acute toxicity was evaluated and scored using
the Common Toxicity Criteria Adverse Events scales
(CTCAE) version 3.0 weekly during each week of radio-
therapy and 3 months after the completion of the radio-
therapy. As acute toxicities can last for 3 months, we
chose to extend our evaluation to 6 months. The worse
GI toxicity (diarrhea, constipation, hemorrhoids, rectal
hemorrhage, anal incontinence, proctitis and anitis) grade
of each patient was analyzed.
Statistical analyses
Mann–Whitney tests were used to determine the rela-
tionship between V25-V75, expressed in % and in cc or
rAUC25–50 and the appearance of any acute GI toxicity
(G ≥ 1).
The optimal rAUC25–50 cut-off value related to acute GI
toxicity was determined using a ROC curve with Youden’s
index. Univariate and multivariate logistic regressions
were used to describe the acute GI toxicity (G ≥ 1) by esti-
mating the Odds-Ratio and 95 % confidence interval (CI).
The multivariate model included the optimal rAUC25–50
cut-off value and the adjustment parameters (age, trans-
urethral resection of the prostate (TURP), hormone ther-
apy and rectum volume). The multivariate model was
internally validated using bootstrapping (170 replications).
All analyses were performed using Stata V13 software
(StataCorp LP, College Station, TX). P values were two-
tailed and considered significant when less than 0.05.
Results
Characterization of toxicity
We observed acute G1, G2 and G3 GI toxicity in 96 pa-
tients (53.3 %), 19 patients (10.6 %) and 2 patients (1.1 %),
respectively. No G4 or G5 GI toxicity was observed.
Among these toxicities, 35.8 % of patients had diarrhea
(29.6 % G1 and 6.2 % G2) and 36.1 % of patients had proc-
titis (32.2 % G1, 3.3 % G2 and 0.6 % G3).
Predictors of acute GI toxicity
The median volumes of the rectum in % and in cc receiv-
ing from 25Gy to 75Gy (increments of 5Gy) are presented
in Table 2.
In the univariate analysis of the entire patient popula-
tion, we found no relationship between any rectal vol-
ume parameters expressed in % and any acute GI
toxicity ≥ grade1 (p from 0.12 to 0.92) (Table 2).
Conversely, when expressed in cc, all rectal volumes
from V25 to V50 correlated significantly with acute GI
toxicity G ≥ 1 (p from 0.018 to 0.045). Beyond 50Gy, no
relationship was found between the volume of rectum
expressed in cc and acute GI toxicity (from 55Gy to 75Gy,
p-values ranged between 0.069 and 0.853) (Table 2).
The rAUC25–50 calculated using the rectum volume
expressed in cc correlated with any grade ≥1 acute GI
toxicity (p = 0.028) (Table 2) while the rAUC25–50 calcu-
lated using rectum volume expressed in % did not correlate
with any acute GI toxicity (data not shown).
Multivariate logistic regression, which included the
variables age, hormone therapy, TURP and rectum vol-
ume (cc), was used. Among these variables, only rectum
volume expressed in cc correlated significantly with
acute GI toxicity (p = 0.041). A Liu/Youden cutting
method showed that patients with a rAUC25–50 >
794 cc.Gy were more likely to develop acute GI toxicity
with IG-IMRT (p = 0.020, [95 % CI: 1.16–5.46]) (Table 3).
These results were validated by a bootstrapping method
using 170 replications (p = 0.019; [95 % CI: 1.16–5.42]).
Discussion
One of the major limits of DVSE is that the DVH curve
can reach V70 by different paths, meaning that doses de-
livered before or beyond this specific endpoint might dif-
fer considerably for the same V70. Given this, for the
same volume of rectum receiving a high dose, one patient
may have a greater rectal volume irradiated at lower doses























Fig. 1 Illustration of rAUC 5Gy calculation from 25 to 30Gy (rAUC25–30). Legends: DVH: Dose Volume Histogram, V25 = volume of rectum receiving
25Gy; V30 = volume of rectum receiving 30Gy; rAUC25–30 = Area Under the Curve of rectal DHV between 25 and 30Gy
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while another may have his rectum spared when evaluated
according to the planning CT. For this reason, the
QUANTEC recommended several DVSE in the context of
dose escalation delivered using 3D conformational radio-
therapy [4]. Recently, like us, Pederson et al. found a lack
of any correlation between standard DVSE criteria and
late GI or GU (genitourinary) toxicities, evaluated using
RTOG and CTCAE V3.0 scales, induced by IMRT [13].
The authors suggested adapting rectum DVH, which cor-
related with late toxicities induced by IMRT. A new par-
ameter related to acute toxicity has yet to be developed.
A number of preliminary clinical studies on high-dose
IMRT and/or high-dose IGRT, like ours, reported very
low rates of acute GI toxicity. In routine practice with
IG-IMRT, acute toxicity is much more frequent than late
toxicity and most patients have grade 1 or 2 toxicity
only, suggesting that it would be better to figure out
what dose/volume parameters best predict any acute GI
toxicity (n = 117 in our series) rather than severe GI tox-
icity only. Although acute toxicities were prospectively
recorded in the follow-up of all of the patients, one limi-
tation of our study arises from the retrospective design,
with drawbacks related to the post hoc scoring of tox-
icity using version 3 of the CTC scale.
Even though toxicity was prospectively scored, one
drawback of our retrospective analyses concerns the major
differences in scoring systems in the literature. Patient-
reported outcomes may be more clinically relevant and we
therefore suggest conducting a new prospective study that
includes both physician- and patient-reported outcomes.
Nevertheless we found a lower rate of acute G ≥ 2 GI
toxicity in our series (12 %), which was very similar to
that observed by Kupelian et al. in 488 patients with
daily IG-IMRT (11 % of G2 acute rectal toxicity) [14]
but lower than that observed by Wortel et al. in 260 pa-
tients treated with IMRT (29 % of G ≥ 2 acute rectal
toxicity) [9]. These two studies used the RTOG toxicity
scoring system. In another report, Singh et al. also con-
firmed less severe rectal symptoms with IGRT compared
with non-IGRT [2].
Table 2 Evaluation of relationship between DVSE and acute gastrointestinal toxicity using univariate logistic regression analysis
Median [range] All patients Patients with acute toxicities Gb = 0 Patients with acute toxicities G≥ 1 p-value
n = 180 n = 63 n = 117
Rectum volumes expressed in %
V25a 68 [27;100] 69.6 [27;100] 67.7 [31.6;100] 0.799
V30 60.9 [24.2;100] 61.6 [24.2;100] 60.7 [25.5;100] 0.860
V35 51.9 [21;100] 51.7 [21.8;99.6] 52.1 [21;100] 0.726
V40 44 [17.6;96.7] 44.3 [19.7;85.3] 43.9 [17.6;96.7] 0.638
V45 35.2 [13.1;82.2] 37.1 [15.5;62.8] 34.8 [13.1;82.2] 0.704
V50 27.8 [8;74.6] 28.3 [9.3;52.9] 27.7 [8;74.6] 0.766
V55 22.4 [5.4;51.2] 23 [5.4;43.6] 22.3 [6.1;51.2] 0.875
V60 17.2 [2.7;40.8] 17.6 [2.7;35.1] 17 [3.4;40.8] 0.918
V65 11.8 [1;29.5] 12.6 [1;29.5] 11.5 [1.2;26.5] 0.582
V70 7.3 [0;23.1] 7.8 [0;23.1] 6.7 [0;19.8] 0.217
V75 0.9 [0;11.4] 1.5 [0;11.4] 0.7 [0;9.1] 0.124
Rectum volumes expressed in cc
V25 53.5 [20.1;223] 48.8 [20.1;114] 57 [20.6;223] 0.039
V30 47.5 [19.5;180.2] 42.8 [19.5;99.8] 50.9 [19.8;180.2] 0.045
V35 41.7 [16.7;150] 37.8 [16.7;86] 42.6 [17.4;150] 0.035
V40 36.1 [11;120.8] 31.9 [11;79] 37.4 [13.9;120.8] 0.025
V45 29.8 [8;101.9] 25.8 [8;69.1] 31.6 [10.2;101.9] 0.018
V50 24.1 [5.9;77] 21.1 [5.9;58.1] 25 [7.6;77] 0.035
V55 19 [4.4;56.4] 17.9 [4.4;47.8] 19.7 [5.8;56.4] 0.069
V60 14.6 [2.4;43.6] 13.1 [2.4;36.3] 15.2 [3.1;43.6] 0.17
V65 10.2 [0.9;36.8] 9.9 [0.9;28.7] 11 [1.3;36.8] 0.387
V70 5.7 [0;29.5] 5.8 [0;20.2] 5.7 [0;29.5] 0.853
V75 0.8 [0;16.2] 0.9 [0;8] 0.6 [0;16.2] 0.232
rAUC25–50 (cc. Gy)
c 972.5 [388.5;3305.3] 835.7 [394.3;2008.8] 1002.4 [388.5;3305.3] 0.028
a Vx = volume of rectum receiving xGy; b Grade using CTC-AE V3.0 validated scale; c Area Under the Curve of rectal DHV between 25 and 50Gy
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Table 3 Optimal rAUC25–50 cut-off value related to acute GI toxicity Grade ≥ 1 determined using a ROC curve (multivariate logistic regression)
Univariate analysis Multivariate analysis Bootstrapping (170 rep)
Acute GIa toxicity
G≥ 1 / N





< =794 cc.Gy 29/59 1 0.002 28 / 58 1 0.020 0.019
> 794 cc.Gy 88/121 2.76 [1.44;5.28] 87 / 120 2.51 [1.16;5.46] [1.16;5.42]
Adjustment variables
Age
< 70 years 57/82 1 0.247 57 / 82 1 0.233 0.226
> = 70 years 60/ 98 0.69 [0.37;1.29] 58 / 96 0.67 [0.35;1.29] [0.35;1.28]
TURPe
No 95/143 1 0.305 95 / 143 1 0.423 0.459
Yes 20/35 0.67 [0.32;1.43] 20 / 35 0.72 [0.33;1.59] [0.31;1.7]
HTf
No 65/104 1 0.411 64 / 103 1 0.757 0.755
Yes 52/76 1.3 [0.7;2.43] 51 / 75 1.11 [0.57;2.16] [0.57;2.15]
Rectum Volume (cc) per unit 1 0.041 1 0.558 0.570
1.01 [1;1.02] 1 [0.99;1.01] [0.99;1.01]












We believe that daily IG-IMRT with a sharper dose
gradient, thanks to daily repositioning on the prostate
isocenter, may ensure that high doses are only delivered
to the same small areas of the rectum as is the case with
brachytherapy. Our results are in keeping with this hy-
pothesis as we found that only the absolute volume of
the rectum (but not the relative volume of the rectum) be-
tween 25Gy and 50Gy correlated with acute GI toxicity
when patients were treated with daily on-line IG-IMRT.
Moreover, these results suggest that intermediate doses
delivered to the rectum may be more relevant than high
doses with daily IG-IMRT.
Conclusions
We have used a simple method to identify a new single
parameter derived from the DVH, in contrast to several
DVSE, that predicts acute GI toxicity: the rAUC25–50 is a
user-friendly tool that can be implemented in any radi-
ation oncology department worldwide.
We recommend that the rAUC25–50 of the entire rectum
should not exceed 794 cc.Gy. This new predictive param-
eter for acute GI toxicity should be validated through a
prospective study.
Abbrevations
3D-CRT: 3-dimensional conformal radiation therapy; CTCAE: Common
terminology criteria for adverse events; CTV: Clinical target volume;
DVH: Dose volume histogram; DVSE: Dose/volume specific endpoints;
GI: Gastrointestinal; GTV: Gross tumor volume; GU: Genito-urinary;
HT: Hormonotherapy; IG-IMRT: Image-guidance intensity modulated
radiation therapy; OAR: Organs at risk; PCa: Prostate cancer; PTV: Planning
target volume; rAUC: Area under the rectal DVH curve; rAUC25–50: rAUC
for doses ranging between 25Gy and 50Gy; RTOG: Radiation Therapy
Oncology Group; TURP: Transurethral resection of the prostate;
Vx: Volume of rectum receiving xGy
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